What’s next for relatlimab?
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.
TG slips out a nasty surprise for investors
Yet another US clinical hold hits, and this time the unlucky recipient is TG Therapeutics.
Sierra’s not-so-nimble Jak scores at last
Momelotinib, a Jak inhibitor that has been through four companies, yields a positive result in its pivotal Momentum trial.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
